Radiotherapy-related toxicity and PROs in prostate cancer patients
Research type
Research Study
Full title
Toxicity and patient reported outcomes in patients receiving radiotherapy for prostate cancer: prospective assessment and audit.
IRAS ID
216169
Contact name
Sanjay Dixit
Contact email
Sponsor organisation
Hull and East Yorkshire Hospitals NHS Trust
Duration of Study in the UK
6 years, 11 months, 29 days
Research summary
A recent study, the Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer (CHHiP) trial, found little difference in the reported side effects and quality of life of patients receiving a shorter 4-week 20 treatment radiotherapy course, compared to the standard 7.4-week 37 treatment course. This Trust did not participate in the original study, but now intends to report on the outcomes of the use of this shorter radiotherapy course on its own patients in comparison to the routinely used schedule. The study will collect data on the early and late side effects experienced by the patients, and also on the patients’ quality of life, at a series of time points before, during and after the radiotherapy treatment.
REC name
North of Scotland Research Ethics Committee 1
REC reference
17/NS/0026
Date of REC Opinion
27 Mar 2017
REC opinion
Further Information Favourable Opinion